Edward White
Edward P. White is the managing director, senior biotechnology analyst, at H.C. Wainwright & Co., where his research coverage focus is on small to mid-cap life sciences companies. He formerly was a senior biotech equity research analyst at FBR & Co. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.
Recent Articles
Pharma Co. Signs License Agreement With Boston Medical Center 12/24/2024
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note.
Biotech Co.'s Sales Could Grow To US$310 Million in 2028 01/10/2024
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
Pharma Co. May Have Accelerated FDA Approval in 2024 12/20/2023
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.
Antibodies from Vaccine Remain Two Years Out 12/06/2023
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
Biotech to Advance New Type 1 Diabetes Drug Into Clinic 10/23/2023
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report.
Trial of New Drug for Acute Leukemia Meets Primary Endpoint 10/05/2023
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report.
New Vaccine for Chikungunya Shown To Be Safe in Youths 09/01/2023
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Recent Quotes
"RLMD has approximately $15.1M in cash and cash equivalents on its balance sheet, which should fund operations through the end of this calendar year."
—
Edward White, FBR & Co.
(2/12/16)
more >
